Insilico Surges After Hong Kong IPO Amid AI Drugmaking Optimism

Artificial Intelligence drug discovery startup Insilico Medicine Cayman TopCo jumped 25% in its Hong Kong trading debut on Tuesday, capping a year of investor frenzy over China’s biotech and AI boom.

Insilico’s shares were priced at HK$24.05 ($3.09) apiece in an initial public offering that raised $293 million. The Hang Seng Biotech Index has surged 67% this year, outperforming the benchmark’s 29% gain.